[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-382074-105":59,"doc-detail-382074-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","an-update-on-the-treatment-of-papillary-renal-cell-carcinoma","An Update on the Treatment of Papillary Renal Cell Carcinoma","","Papillary renal cell carcinoma (pRCC) is the second-most common subtype of kidney cancer after clear cell renal cell carcinoma, accounting for about 15% of cases. Despite therapeutic advances, including targeted therapies and immune checkpoint inhibitors, outcomes have improved more slowly than in ccRCC, partly due to heterogeneity across pRCC subtypes. This review summarizes key biological characteristics and the most impactful clinical trials to date, and highlights ongoing trials shaping future treatment directions.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/an-update-on-the-treatment-of-papillary-renal-cell-carcinoma/382074/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/an-update-on-the-treatment-of-papillary-renal-cell-carcinoma/382074.png","ImageObject",300,407,{"name":92,"@type":93},"hdkawk","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is papillary renal cell carcinoma (pRCC) and how common is it?","Question",{"text":112,"@type":113},"pRCC is the second-most common kidney cancer subtype after clear cell renal cell carcinoma, representing about 15% of kidney cancers. It is one of the main forms of non-clear cell RCC.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why have treatment advances for pRCC lagged behind those for ccRCC?",{"text":117,"@type":113},"Progress has lagged in part because pRCC consists of heterogeneous subtypes with distinct biology. This complexity has influenced the development and interpretation of therapies and trials.",{"name":119,"@type":110,"acceptedAnswer":120},"What does the review focus on besides biological characteristics?",{"text":121,"@type":113},"The review outlines key biological characteristics and discusses the most impactful clinical trials. It also looks ahead to several highly anticipated ongoing trials in pRCC.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},382074,1790319061,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41},3985747859855,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","cancers   \nReview  \nAn Update on the Treatment of Papillary Renal Cell Carcinoma  \nNeal S. Chawla 1,†, Nicolas Sayegh 2,†, Sweta Prajapati 1, Elyse Chan 1, Sumanta K. Pal 1  \nand Alexander Chehrazi-Raffle 1, *  \nCitation: Chawla, N.S.; Sayegh, N.; Prajapati, S.; Chan, E.; Pal, S.K.; Chehrazi-Raffle, A. An Update on the Treatment of Papillary Renal Cell Carcinoma. Cancers 2023, 15, 565 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)cancers15030565  \nAcademic Editor: Fabrizio Fabrizi  \nReceived: 4 December 2022  \nRevised: 11 January 2023  \nAccepted: 15 January 2023  \nPublished: 17 January 2023  \nCopyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA  \n2 Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA  \n* Correspondence: achehraziraffl[e@coh.org](e@coh.org); Tel.: +1-626-256-4772; Fax: +1-626-301-8233 † These authors contributed equally to this work.  \nSimple Summary: Papillary renal cell carcinoma is the second most common type of kidney cancer, after clear cell kidney cancer. Given that it is relatively rare, studying this disease has been quite a challenge. New treatments and techniques for studying papillary kidney cancer have led to some meaningful improvements in therapy for this disease. In this review article, we summarize some of the historical studies in this space, and look ahead to three upcoming trials in papillary renal cell carcinoma.  \nAbstract: Papillary renal cell carcinoma (pRCC) is the second-most common subtype of kidney cancer following clear cell renal cell carcinoma (ccRCC), representing 15% of kidney cancers. Despite advances in therapy, including combination strategies with targeted therapies and immune checkpoint inhibitors, progress has lagged behind that of ccRCC. This is in part due to the heterogenous nature of the various subtypes of pRCC. More recently, investigators have turned efforts towards histology and biology-based trials. In this review, we outline some of the distinct biological characteristics of pRCC and discuss the most impactful clinical trials to date. Finally, we look ahead to several highly anticipated ongoing trials in pRCC.  \nKeywords: papillary; renal cell carcinoma  \n1. Introduction  \nThere will be an estimated 79,000 cases of renal cell carcinoma (RCC) in 2022, of which non-clear renal cell carcinoma (nccRCC) will represent approximately 25–30%[1,2] . The most recent global statistics indicate that there were over 400,000 cases of RCC in 2020 [3] . nccRCC is comprised of several subtypes, including papillary (pRCC), chromophobe, collecting duct, renal medullary, translocation, and unclassified. pRCC represents 15% of kidney cancers and the most common type of nccRCC [4] .  \npRCC is diagnosed most commonly between the ages of 50–70 and occurs more often in men [5] . These tumors are often characterized radiologically by calcification and are frequently multifocal in nature [6,7] . Although retrospective and limited in sample size, Dudani and colleagues' analysis of the International Metastatic RCC Database Consortium (IMDC) suggested that metastatic pRCC is associated with worse survival compared to metastatic clear cell RCC (ccRCC), regardless of the site of metastasis [8] . pRCC has a threefold-higher incidence among Black people than White people [5] . Additionally, Asian Americans have been found to have an increased risk of pRCC based on data from a regional database with nearly 10,000 patients [9] .  \nIn metastatic renal cell carcinoma ","cbCailYjJ93dv4KR","https://ap.wps.com/l/cbCailYjJ93dv4KR","pdf",1162327,12,"English","# Review\n## Introduction\n## Biological Subtypes","[{\"question\":\"What is papillary renal cell carcinoma (pRCC) and how common is it?\",\"answer\":\"pRCC is the second-most common kidney cancer subtype after clear cell renal cell carcinoma, representing about 15% of kidney cancers. It is one of the main forms of non-clear cell RCC.\"},{\"question\":\"Why have treatment advances for pRCC lagged behind those for ccRCC?\",\"answer\":\"Progress has lagged in part because pRCC consists of heterogeneous subtypes with distinct biology. This complexity has influenced the development and interpretation of therapies and trials.\"},{\"question\":\"What does the review focus on besides biological characteristics?\",\"answer\":\"The review outlines key biological characteristics and discusses the most impactful clinical trials. It also looks ahead to several highly anticipated ongoing trials in pRCC.\"}]","An Update on the Treatment of Papillary Renal Cell Carcinoma | PDF",1790248885]